Tarazi Riyad, Ridha Mustafa, Shammsah Mohammad, AlHumood Khaldoon, Tesreni Jean, Badawy Mohamed, Mohamed Amir, Maher Adel
Department of Cardiac Surgery, Al-Dabbous Cardiac Center, Kuwait City, Kuwait.
Department of Cardiology, Al-Dabbous Cardiac Center, Kuwait City, Kuwait.
J Thorac Dis. 2018 Jun;10(Suppl 15):S1758-S1762. doi: 10.21037/jtd.2017.12.54.
Heart Failure is an epidemic with a current prevalence of over 5.8 million patients in the USA and almost 23 million patients worldwide, with high associated mortality risks. The severe shortage of donor organs for cardiac transplants and increasing number of heart failure patients has led to the increasing popularity of left ventricular assist device (LVAD) therapy for treatment of end-stage heart failure patients. This paper describes our initial clinical experience with LVAD therapy of heart failure patients at our clinic.
Ten patients (eight males and two females) with a mean age of 48 years (range, 14-68 years) were implanted with LVADs as bridge to transplantation (BT) or destination therapy (DT) at our clinic between January 2015 and October 2017.
Preliminary results were very promising with 0% 30-day mortality rates and no major surgical complications or LVAD thrombosis.
Such results of LVAD implantation in Kuwait indicate the feasibility of establishing De Novo LVAD programs in low volume LVAD centers (≤10 implants/year) with promising results and offer a new era of hope for treating advanced heart failure patients.
心力衰竭是一种流行病，目前在美国有超过580万患者患病，全球近2300万患者患病，伴有高相关死亡风险。心脏移植供体器官的严重短缺以及心力衰竭患者数量的增加，导致左心室辅助装置（LVAD）治疗终末期心力衰竭患者的应用越来越普遍。本文描述了我们诊所对心力衰竭患者进行LVAD治疗的初步临床经验。
2015年1月至2017年10月期间，我们诊所对10例患者（8例男性和2例女性）进行了LVAD植入，平均年龄48岁（范围14 - 68岁），作为移植桥接（BT）或终末治疗（DT）。
初步结果非常令人鼓舞，30天死亡率为0%，无重大手术并发症或LVAD血栓形成。
在科威特进行LVAD植入的这些结果表明，在低容量LVAD中心（每年植入≤10例）建立全新LVAD项目是可行的，结果令人鼓舞，并为治疗晚期心力衰竭患者带来了新的希望时代。
